Vascular Pharmaceuticals, a startup focusing on development of treatments for complications from diabetes, has raised $3 million in new financing.

The funding, which is debt, was disclosed in a securities filing.

The company raised $15 million in a venture capital round last year that targeted a $25 million total. The round had opened in 2013.

Six investors participated in the latest financing, the company said.

Intersouth partners, which is based in Durham and invested previously, is an investor in the company.

Vascular launched a Phase 2 Clinical Trial of VPI-2690B for Diabetic Nephropathy in November 2014.